SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

FRANKFURT: German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 ...

FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for ...

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 million upfront and up to $1.7 billion overall. Biohaven signed a $600 ...

Why is that? That's because big pharmaceutical powerhouse Merck KGaA had agreed to acquire SpringWorks Therapeutics for a purchase price of $47 per share, which represents an equity value of $3.9 ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare ...

Merck KGaA will acquire SpringWorks Therapeutics, a US biopharmaceutical company focused on developing treatments for rare tumors. 1 According to a press release from SpringWorks, this will allow the ...

Under the agreement, Merck will pay $47 per share in cash, based on SpringWorks’ cash balance as of Dec. 31, 2024, and a 26% premium on SpringWorks’ unaffected 20-day volume-weighted average ...

Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business – – SpringWorks Therapeutics is a U.S.